Dermatol. 2020;156(10):1079-1085. doi: 10.1001/jamadermatol.2020.1795.
17. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013; 27(9):1071-1080. doi: 10.1111/jdv.12082.
18. Garbe C, Peris K, Soura E, et al. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. J Eur Acad Dermatol Venereol. 2020;34(10):2183-2197. doi: 10.1111/jdv.16849.
19. Lucas AS, Ciccolini K. The role of oncodermatology in care of patients receiving cancer therapy. Semin Oncol Nurs. 2017;22(4):393-401. doi: 10.1016/j.soncn.2017.08.001.
20. Aizman L, Nelson K, Sparks AD, Friedman AJ. The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey. J Drugs Dermatol. 2020;19(5):477- 482.
21. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020;82(4): 994-996. doi: 10.1016/j.jaad.2019.09.026.
22. Barrios DM, Phillips GS, Feites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340-1347. doi: 10.1111/jdv.16159.
23. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at Memorial Sloan Kettering Cancer Center. J Am Acad Dermatol. 2017;76(6):AB45. doi: 10.1016/j.jaad.2017.04.196.
24. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter. 2020; 10:1-12. https://www.skintherapyletter.com/wp-content/uploads/2020/12/STL-Supp-SkinCareOnc-v2- correction.pdf
25. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian skin management in oncology (CaSMO) algorithm for patients with oncology treatment-related skin toxicities. Skin Ther Letter. 2021; 3:1-10.
26. Lacouture ME, Choi J, Ho A et al. US cutaneous oncodermatology management (USCOM): A practical algorithm. J Drugs Dermatol. 2021;20(9):3ss-s19. doi: 10.36849/jdd.6229.
27. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. Lacouture ME, ed. Wiley Blackwell; 2014.
28. Wolf SL, Qin R, Menon SP et al. Placeboâ€controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabineâ€induced handâ€foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28(35):5182-5187. doi: 10.1200/ JCO.2010.31.1431.
29. Macedo LT, Lima JPN, dos Santos LV et al. Prevention strategies for chemotherapyâ€induced handâ€foot syndrome: A systematic review and metaâ€analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585-1593. doi: 10.1007/s00520-014-2129-z.
30. Chen HM, Tsai CM, Wu YC et al. Randomised controlled trial on the effectiveness of homeâ€based walking exercise on anxiety, depression and cancerâ€related symptoms in patients with lung cancer. Br J Cancer. 2015;112(3):438-445. doi: 10.1038/bjc.2014.612.
31. Berger A, Regueiro C, Hijal T, et al. Interest of supportive and barrier protective skin care products in the daily prevention and treatment of cutaneous toxicity during radiotherapy for breast cancer. Breast Cancer (Auckl). 2018;12:1178223417752772.. doi: 10.1177/1178223417752772.
32. Wohlrab J, Lueftner D, Johne A, et al. The advantage of a proactive, barrier-protective, supportive skin care in patients with breast cancer on chemotherapy. Onkologie. 2011;34: 62.
33. Lüftner D, Dell'Acqua V, Selle F, et al. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. Onco Targets Ther. 2018 17;11:5865-5872. doi: 10.2147/OTT.S155438. 34. Baumann BC, Verginadis II, Zeng C, et al. Assessing the validity of clinician advice that patients avoid the use of topical agents before daily radiotherapy treatments. JAMA Oncol. 2018;4(12):1742-1748. doi: 10.1001/jamaoncol.2018.4292.
35. Salzmann M, Marmé F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care (Basel). 2019;14:72-77. doi: 10.1159/000497232
36. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142. doi: 10.1093/annonc/mdx225.
37. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immunotherapy-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126. PIMD: 34724392.
38. Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines insights: Management of immunotherapyrelated toxicities, Version 1.2020. J Natl Compr Cancer Netw. 2020;18(3):230-241. doi: 10.6004/ jnccn.2020.0012
39. Hijal T, Sauder MB, Andriessen A, Claveau J, Lynde CW. Canadian Skin Management in Oncology Group (Casmo) algorithm for the prevention and management of acute radiation dermatitis. Skin Ther Letter; 2021;11:1-13. https://www.skintherapyletter.com/wp-content/uploads/2021/11/STL-Suppl-CaSMOAlgorithm- RD.pdf
40. Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746-2758. doi: 10.1200/JCO.18.02141.
41. Rosenthal A, Irailevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for a treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-567. doi: 10.1016/j. jaad.2019.02.047.
42. Leventhal J, Young MR. Radiation Dermatitis: Recognition, Prevention, and Management. Oncology (Williston Park). 2017;31(12):885-887, 894-899.
43. Ferreira MN, Ramseier JY, Leventhal S. Dermatologic conditions in women receiving systemic cancer therapy. Int J Women Dermatol. 2019;5(5):285-307. doi: 10.1016/j.ijwd.2019.10.003.
44. Friese CR, Harrison JM, Janz NK, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123(11):1925-1934. doi: 10.1002/ cncr.30547.
45. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724-728. doi: 10.1001/ jamadermatol.2018.5071.
46. Biswal SG, Mehta RD. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J Dermatol. 2018;63(1):41-6. doi: 10.4103/ijd.IJD_65_17.
47. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018;50(4):1186-1193. doi: 10.4143/ crt.2017.435.
48. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse cutaneous drug reactions: An updated review on risks associated with anticancer targeted therapy or immunotherapy. J Immunol Res. 2018;2018:5376476. doi: 10.1155/2018/5376476.
49. Yagasaki K, Komatsu H, Hamamoto Y. Targeted therapy-induced facial skin toxicities: Impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172-177. doi: 10.4103/apjon.apjon_74_17.
50. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(8): 1351-1357. doi: 10.1200/JCO.2008.21.7828.
51. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
52. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158-176. doi: 10.1111/cup.12858.
53. Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):e000457. doi: 10.1136/esmoopen-2018-000457.
54. Rzepecki A, Birnbaum M, Ohri N, et al. Characterizing the Effects of Radiation Dermatitis on Quality of Life: A Prospective Survey-Based Study. J Am Acad Dermatol. 2022;86(1):161-163. doi: 10.1016/j. jaad.2019.03.011.
55. Ho PH, Lin IC, Yang X, Cho YT, Chu CY. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol. 2019;33(1):204-212. doi: 10.1111/jdv.15121.
56. Wu J, Freitez-Martinez A, Hellmann MD, et al. Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors. J Clin Oncol. 2018;36(15_suppl):e2209. doi: 10.1200/JCO.2018.36.15_suppl. e22093.
57. Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. J Am Acad Dermatol. 2018;79(6):1047-1052. doi: 10.1016/j.jaad.2018.05.035. 58. Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393-403. doi: 10.1016/ S1470-2045(17)30015-3.
59. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res. 2016;22(4):886-894. doi: 10.1158/1078-0432.
60. Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi: 10.1007/s40257-013-0021-0.
61. Drilon A, Eaton AA, Schindler K, et al. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016;122(8):1228- 1237. doi: 10.1002/cncr.29918.
62. Müller V, Fuxius S, Steffens CC, et al. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: Data from a German nonâ€interventional surveillance study. Oncol Res Treat. 2014;37(12):748- 755. doi: 10.1159/000369487.
63. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 April 1, 2018. Updated April 19, 2021. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
64. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339-346. doi: 10.1111/ cup.12666.
65. Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003.
66. Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol. 2017;42(3):309-312. doi: 10.1111/ced.13042.
67. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-384. doi: 10.1111/cup.12876.
68. Chan RJ, Blades R, Jones L, et al. A single-blind, randomised controlled trial of StrataXRT® – a siliconebased film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Radiother Oncol. 2019;139:72–78. doi: 10.1016/j.radonc.2019.07.014.
69. Herst PM, Bennett NC, Sutherland AE, Peszynski RI, Paterson DB, Jasperse ML. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiother Oncol. 2014;110:137-143. doi: 10.1016/j.radonc.2014.01.005.
70. Jensen JM, Gau T, Schultze J, et al. Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial. Strahlenther Onkol. 2011;187(6):378-384. doi: 10.1007/s00066-011-2224-8.
71. Zenda S, Yamaguchi T, Yokota T, et al. Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. BMC Cancer. 2018;18(1):873. doi: 10.1186/ s12885-018-4763-1.
72. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25. doi: 10.1016/j.ejca.2016.02.010.
73. Ho AY, Olm-Shipman M, Zhang Z, et al. A randomized trial of mometasone furoate 0.1% to reduce highgrade acute radiation dermatitis in breast cancer patients receiving postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2018;101(2):325–333. doi: 10.1016/j.ijrobp.2018.02.006.
74. Wooding H, Yan J, Yuan L, et al. The effect of Mepitel film on acute radiation-induced skin reactions in head neck cancer patients: a feasibility study. Br J Radiol. 2018;91(1081):20170298. doi: 10.1259/bjr.20170298.
75. Cruceriu D, Balacescu O, Rakosky E. Calendula officinalis: Potential roles in cancer treatment palliative care. Integr Cancer Ther. 2018;17(4):1068-1078. doi: 10.1177/1534735418803766.
76. Menêses AG de, Reis PED dos, Guerra ENS, Canto GDL, Ferreira EB. Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis. Rev Latino-Am Enfermagem. 2018;26(0). doi: 10.1590/1518-8345.2035.2929.
77. Sharp L, Finnilä K, Johansson H, Abrahamsson M, Hatschek T, Bergenmar M. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions—results from a randomised blinded trial. Eur J Oncol Nurs. 2013;17(4):429-435. doi: 10.1016/j.ejon.2012.11.003.
78. Schneider F, Danski MTR, Vayego SA. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled clinical trial [in Portuguese]. Rev Esc Enferm USP. 2015;49(2):221-228. doi: 10.1590/S0080-623420150000200006.
79. Graham PH, Plant N, Graham JL, et al. A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: trans Tasman Radiation Oncology Group (TROG) 04.01. Int J Radiat Oncol Biol Phys. 2013;86(1): 45-50. doi: 10.1016/j.ijrobp.2012.12.009.
80. Chan RJ, Mann J, Tripcony L, et al. Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial. Int J Radiat Oncol Biol Phys. 2014;15;90(4):756-764. doi: 10.1016/j.ijrobp.2014.06.034.
81. Lam AC, Yu E, Vanwynsberghe D, et al. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy. Cureus. 2019;11(6):e4807. doi: 10.7759/cureus.4807.
82. Kornhaber, R, Visentin, D, Thapa, DK, et al. Cosmetic camouflage improves quality of life among patients with skin disfigurement: a systematic review. Body Image. 2018;27:98-108. doi: 10.1016/j. bodyim.2018.08.004.
83. Gholizadeh S, Rice DB, Carboni-Jiménez A, et al. Effects of cosmetic and other camouflage interventions on appearance-related and psychological outcomes among adults with visible differences in appearance: a systematic review. British Med J Open. 2021;11(3): e046634. doi:10.1136/bmjopen-2020-046634.
84. Chen, SC, Huang, BS, Lin, CY, et al. Psychosocial effects of a skin camouflage program in female survivors with head and neck cancer: a randomized controlled trial. Psychooncology. 2016;26(9):1376–1383. doi: 10.1002/pon.4308.
85. Wakeda T, Okamura T, Kawahara T, Heike Y. Camouflage makeup improves quality of life in cancer patients with treatment-related skin changes. Tumori. 2020;106(2):95-100. doi: 10.1177/0300891619867844.
86. Derbyshire E. Innovations in skin camouflaging echniques: Where are we scientifically? Int J Cos Sci. 2019;41(6):526-533. doi: 10.1111/ ics.12575
17. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013; 27(9):1071-1080. doi: 10.1111/jdv.12082.
18. Garbe C, Peris K, Soura E, et al. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. J Eur Acad Dermatol Venereol. 2020;34(10):2183-2197. doi: 10.1111/jdv.16849.
19. Lucas AS, Ciccolini K. The role of oncodermatology in care of patients receiving cancer therapy. Semin Oncol Nurs. 2017;22(4):393-401. doi: 10.1016/j.soncn.2017.08.001.
20. Aizman L, Nelson K, Sparks AD, Friedman AJ. The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey. J Drugs Dermatol. 2020;19(5):477- 482.
21. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020;82(4): 994-996. doi: 10.1016/j.jaad.2019.09.026.
22. Barrios DM, Phillips GS, Feites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340-1347. doi: 10.1111/jdv.16159.
23. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at Memorial Sloan Kettering Cancer Center. J Am Acad Dermatol. 2017;76(6):AB45. doi: 10.1016/j.jaad.2017.04.196.
24. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter. 2020; 10:1-12. https://www.skintherapyletter.com/wp-content/uploads/2020/12/STL-Supp-SkinCareOnc-v2- correction.pdf
25. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian skin management in oncology (CaSMO) algorithm for patients with oncology treatment-related skin toxicities. Skin Ther Letter. 2021; 3:1-10.
26. Lacouture ME, Choi J, Ho A et al. US cutaneous oncodermatology management (USCOM): A practical algorithm. J Drugs Dermatol. 2021;20(9):3ss-s19. doi: 10.36849/jdd.6229.
27. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. Lacouture ME, ed. Wiley Blackwell; 2014.
28. Wolf SL, Qin R, Menon SP et al. Placeboâ€controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabineâ€induced handâ€foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28(35):5182-5187. doi: 10.1200/ JCO.2010.31.1431.
29. Macedo LT, Lima JPN, dos Santos LV et al. Prevention strategies for chemotherapyâ€induced handâ€foot syndrome: A systematic review and metaâ€analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585-1593. doi: 10.1007/s00520-014-2129-z.
30. Chen HM, Tsai CM, Wu YC et al. Randomised controlled trial on the effectiveness of homeâ€based walking exercise on anxiety, depression and cancerâ€related symptoms in patients with lung cancer. Br J Cancer. 2015;112(3):438-445. doi: 10.1038/bjc.2014.612.
31. Berger A, Regueiro C, Hijal T, et al. Interest of supportive and barrier protective skin care products in the daily prevention and treatment of cutaneous toxicity during radiotherapy for breast cancer. Breast Cancer (Auckl). 2018;12:1178223417752772.. doi: 10.1177/1178223417752772.
32. Wohlrab J, Lueftner D, Johne A, et al. The advantage of a proactive, barrier-protective, supportive skin care in patients with breast cancer on chemotherapy. Onkologie. 2011;34: 62.
33. Lüftner D, Dell'Acqua V, Selle F, et al. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. Onco Targets Ther. 2018 17;11:5865-5872. doi: 10.2147/OTT.S155438. 34. Baumann BC, Verginadis II, Zeng C, et al. Assessing the validity of clinician advice that patients avoid the use of topical agents before daily radiotherapy treatments. JAMA Oncol. 2018;4(12):1742-1748. doi: 10.1001/jamaoncol.2018.4292.
35. Salzmann M, Marmé F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care (Basel). 2019;14:72-77. doi: 10.1159/000497232
36. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142. doi: 10.1093/annonc/mdx225.
37. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immunotherapy-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126. PIMD: 34724392.
38. Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines insights: Management of immunotherapyrelated toxicities, Version 1.2020. J Natl Compr Cancer Netw. 2020;18(3):230-241. doi: 10.6004/ jnccn.2020.0012
39. Hijal T, Sauder MB, Andriessen A, Claveau J, Lynde CW. Canadian Skin Management in Oncology Group (Casmo) algorithm for the prevention and management of acute radiation dermatitis. Skin Ther Letter; 2021;11:1-13. https://www.skintherapyletter.com/wp-content/uploads/2021/11/STL-Suppl-CaSMOAlgorithm- RD.pdf
40. Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746-2758. doi: 10.1200/JCO.18.02141.
41. Rosenthal A, Irailevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for a treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-567. doi: 10.1016/j. jaad.2019.02.047.
42. Leventhal J, Young MR. Radiation Dermatitis: Recognition, Prevention, and Management. Oncology (Williston Park). 2017;31(12):885-887, 894-899.
43. Ferreira MN, Ramseier JY, Leventhal S. Dermatologic conditions in women receiving systemic cancer therapy. Int J Women Dermatol. 2019;5(5):285-307. doi: 10.1016/j.ijwd.2019.10.003.
44. Friese CR, Harrison JM, Janz NK, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123(11):1925-1934. doi: 10.1002/ cncr.30547.
45. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724-728. doi: 10.1001/ jamadermatol.2018.5071.
46. Biswal SG, Mehta RD. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J Dermatol. 2018;63(1):41-6. doi: 10.4103/ijd.IJD_65_17.
47. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018;50(4):1186-1193. doi: 10.4143/ crt.2017.435.
48. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse cutaneous drug reactions: An updated review on risks associated with anticancer targeted therapy or immunotherapy. J Immunol Res. 2018;2018:5376476. doi: 10.1155/2018/5376476.
49. Yagasaki K, Komatsu H, Hamamoto Y. Targeted therapy-induced facial skin toxicities: Impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172-177. doi: 10.4103/apjon.apjon_74_17.
50. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(8): 1351-1357. doi: 10.1200/JCO.2008.21.7828.
51. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
52. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158-176. doi: 10.1111/cup.12858.
53. Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):e000457. doi: 10.1136/esmoopen-2018-000457.
54. Rzepecki A, Birnbaum M, Ohri N, et al. Characterizing the Effects of Radiation Dermatitis on Quality of Life: A Prospective Survey-Based Study. J Am Acad Dermatol. 2022;86(1):161-163. doi: 10.1016/j. jaad.2019.03.011.
55. Ho PH, Lin IC, Yang X, Cho YT, Chu CY. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol. 2019;33(1):204-212. doi: 10.1111/jdv.15121.
56. Wu J, Freitez-Martinez A, Hellmann MD, et al. Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors. J Clin Oncol. 2018;36(15_suppl):e2209. doi: 10.1200/JCO.2018.36.15_suppl. e22093.
57. Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. J Am Acad Dermatol. 2018;79(6):1047-1052. doi: 10.1016/j.jaad.2018.05.035. 58. Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393-403. doi: 10.1016/ S1470-2045(17)30015-3.
59. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res. 2016;22(4):886-894. doi: 10.1158/1078-0432.
60. Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi: 10.1007/s40257-013-0021-0.
61. Drilon A, Eaton AA, Schindler K, et al. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016;122(8):1228- 1237. doi: 10.1002/cncr.29918.
62. Müller V, Fuxius S, Steffens CC, et al. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: Data from a German nonâ€interventional surveillance study. Oncol Res Treat. 2014;37(12):748- 755. doi: 10.1159/000369487.
63. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 April 1, 2018. Updated April 19, 2021. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
64. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339-346. doi: 10.1111/ cup.12666.
65. Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003.
66. Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol. 2017;42(3):309-312. doi: 10.1111/ced.13042.
67. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-384. doi: 10.1111/cup.12876.
68. Chan RJ, Blades R, Jones L, et al. A single-blind, randomised controlled trial of StrataXRT® – a siliconebased film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Radiother Oncol. 2019;139:72–78. doi: 10.1016/j.radonc.2019.07.014.
69. Herst PM, Bennett NC, Sutherland AE, Peszynski RI, Paterson DB, Jasperse ML. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiother Oncol. 2014;110:137-143. doi: 10.1016/j.radonc.2014.01.005.
70. Jensen JM, Gau T, Schultze J, et al. Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial. Strahlenther Onkol. 2011;187(6):378-384. doi: 10.1007/s00066-011-2224-8.
71. Zenda S, Yamaguchi T, Yokota T, et al. Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. BMC Cancer. 2018;18(1):873. doi: 10.1186/ s12885-018-4763-1.
72. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25. doi: 10.1016/j.ejca.2016.02.010.
73. Ho AY, Olm-Shipman M, Zhang Z, et al. A randomized trial of mometasone furoate 0.1% to reduce highgrade acute radiation dermatitis in breast cancer patients receiving postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2018;101(2):325–333. doi: 10.1016/j.ijrobp.2018.02.006.
74. Wooding H, Yan J, Yuan L, et al. The effect of Mepitel film on acute radiation-induced skin reactions in head neck cancer patients: a feasibility study. Br J Radiol. 2018;91(1081):20170298. doi: 10.1259/bjr.20170298.
75. Cruceriu D, Balacescu O, Rakosky E. Calendula officinalis: Potential roles in cancer treatment palliative care. Integr Cancer Ther. 2018;17(4):1068-1078. doi: 10.1177/1534735418803766.
76. Menêses AG de, Reis PED dos, Guerra ENS, Canto GDL, Ferreira EB. Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis. Rev Latino-Am Enfermagem. 2018;26(0). doi: 10.1590/1518-8345.2035.2929.
77. Sharp L, Finnilä K, Johansson H, Abrahamsson M, Hatschek T, Bergenmar M. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions—results from a randomised blinded trial. Eur J Oncol Nurs. 2013;17(4):429-435. doi: 10.1016/j.ejon.2012.11.003.
78. Schneider F, Danski MTR, Vayego SA. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled clinical trial [in Portuguese]. Rev Esc Enferm USP. 2015;49(2):221-228. doi: 10.1590/S0080-623420150000200006.
79. Graham PH, Plant N, Graham JL, et al. A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: trans Tasman Radiation Oncology Group (TROG) 04.01. Int J Radiat Oncol Biol Phys. 2013;86(1): 45-50. doi: 10.1016/j.ijrobp.2012.12.009.
80. Chan RJ, Mann J, Tripcony L, et al. Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial. Int J Radiat Oncol Biol Phys. 2014;15;90(4):756-764. doi: 10.1016/j.ijrobp.2014.06.034.
81. Lam AC, Yu E, Vanwynsberghe D, et al. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy. Cureus. 2019;11(6):e4807. doi: 10.7759/cureus.4807.
82. Kornhaber, R, Visentin, D, Thapa, DK, et al. Cosmetic camouflage improves quality of life among patients with skin disfigurement: a systematic review. Body Image. 2018;27:98-108. doi: 10.1016/j. bodyim.2018.08.004.
83. Gholizadeh S, Rice DB, Carboni-Jiménez A, et al. Effects of cosmetic and other camouflage interventions on appearance-related and psychological outcomes among adults with visible differences in appearance: a systematic review. British Med J Open. 2021;11(3): e046634. doi:10.1136/bmjopen-2020-046634.
84. Chen, SC, Huang, BS, Lin, CY, et al. Psychosocial effects of a skin camouflage program in female survivors with head and neck cancer: a randomized controlled trial. Psychooncology. 2016;26(9):1376–1383. doi: 10.1002/pon.4308.
85. Wakeda T, Okamura T, Kawahara T, Heike Y. Camouflage makeup improves quality of life in cancer patients with treatment-related skin changes. Tumori. 2020;106(2):95-100. doi: 10.1177/0300891619867844.
86. Derbyshire E. Innovations in skin camouflaging echniques: Where are we scientifically? Int J Cos Sci. 2019;41(6):526-533. doi: 10.1111/ ics.12575
AUTHOR CORRESPONDENCE
Anneke Andriessen PhD anneke.a@tiscali.nl
